Analyst Ratings February 20, 2026

RBC Sticks With Outperform on Brookdale Senior Living, Calls Dip a Buying Opportunity

Analyst reiterates $17 price target and cites management progress on pricing, occupancy and operations despite recent share weakness

By Derek Hwang BKD
RBC Sticks With Outperform on Brookdale Senior Living, Calls Dip a Buying Opportunity
BKD

RBC Capital maintained its Outperform rating on Brookdale Senior Living (NYSE: BKD) and held a $17.00 price target, saying it views the recent post-earnings sell-off as an opportunity to buy on weakness. The firm highlighted management commentary on pricing and occupancy and an operational focus that it believes will support mid-teens adjusted EBITDA growth through 2028 from a $451 million base.

Key Points

  • RBC Capital reaffirmed an Outperform rating on Brookdale Senior Living (BKD) and kept a $17.00 price target.
  • RBC highlighted management’s pricing and occupancy commentary and a renewed operational focus as drivers of long-term return on investment.
  • Brookdale reported Q4 2025 results with EPS of -$0.17 and revenue of $754.09 million, both slightly ahead of expectations; the stock fell in premarket trading.

Summary

RBC Capital reiterated an Outperform rating on Brookdale Senior Living stock (NYSE: BKD) and kept a $17.00 target price, signaling confidence in the company’s longer-term trajectory despite a recent decline in the share price. The firm indicated it is willing to add on pullbacks after the stock dropped following fourth-quarter results and the maintenance of 2026 guidance.


Analyst view and rationale

RBC Capital described itself as buyers on weakness, saying it remains comfortable with Brookdale’s strategic direction. The firm pointed to constructive management commentary around pricing and occupancy, as well as an increased emphasis on operations, and said these elements underpin its continued positive view. RBC reiterated its long-term thesis and the Outperform rating, with commentary attributed to analyst Ben Hendrix.

RBC expects Brookdale to be positioned to reach mid-teens adjusted EBITDA growth through 2028, building from a current adjusted EBITDA of $451 million. That target frames the firm’s confidence in the company’s operating plan and future earnings potential.


Market performance and valuation notes

At the time of the note, the stock was trading at $14.68 and had fallen 9.45% over the prior week, despite a substantial one-year return of 174%. RBC sees room for outperformance as baby boomer-driven industry demand increases and supply constraints persist; however, InvestingPro analysis cited in the commentary flagged the possibility that the shares are overvalued at current levels.


Recent financial results and market reaction

Brookdale reported fourth-quarter 2025 results that beat consensus on both EPS and revenue. The company posted an EPS of -$0.17, modestly better than the forecasted -$0.18, and reported revenue of $754.09 million, slightly above expectations. Even with the upside to estimates, the stock fell in premarket trading following the release.

There were no announcements regarding mergers or acquisitions, and no recent upgrades or downgrades from other analyst firms were reported alongside these developments.


Takeaway

RBC’s reiteration reflects continued conviction in Brookdale’s operational and pricing progress and a forecast for mid-teens EBITDA growth through 2028 from a $451 million base. The firm framed the recent share price weakness as a buying opportunity while noting differing views on valuation from InvestingPro analysis.

Risks

  • The stock experienced a near-term sell-off following fourth-quarter results and guidance maintenance, indicating market sensitivity to earnings and outlook - this affects equity investors and the real estate and healthcare REIT sectors.
  • InvestingPro analysis noted the possibility the shares are overvalued at current levels, presenting valuation risk for prospective buyers - relevant to equity and institutional investors focused on senior housing.
  • No recent M&A activity or analyst upgrades/downgrades were reported, leaving potential catalysts limited in the near term - impacting investor sentiment in the senior living and healthcare real estate sectors.

More from Analyst Ratings

BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 Supreme Court Ruling Boosts Steve Madden Outlook, Analysts Say Feb 20, 2026 UBS Lowers Carvana Price Target Citing Higher Costs, Keeps Buy Rating Feb 20, 2026 UBS Lifts Cheesecake Factory Price Target as Margins Improve, Keeps Sell Rating Feb 20, 2026